Rocket Pharmaceuticals highlighted new RP-A501 clinical findings and development milestones for Danon disease. The company shared the updates during its October 6 investor webinar. Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) develops genetic medicines for rare and life-threatening diseases. The company operates as a fully integrated commercial-stage biotechnology company.
During the webinar, Rocket outlined progress toward its FDA-aligned pivotal Phase 2 trial. The company also discussed longer-term Phase 1 findings. In addition, Rocket reported initial safety observations from the first three patients treated under its modified protocol. These patients received the recalibrated dose of RP-A501.
RP-A501 Pivotal Phase 2 Trial Progress
The FDA-aligned pivotal efficacy population includes 12 male patients. These patients will receive commercial-grade RP-A501 at the recalibrated dose. The first three patients treated under the modified protocol count toward this efficacy population. Therefore, the company continues to advance the pivotal study. Trial success requires at least seven patients to meet both response criteria. Patients must meet these criteria at the 12-month assessment.
First, patients must demonstrate myocardial LAMP2 protein expression of at least Grade 1. Second, patients must achieve at least a 10% reduction in left ventricular mass index. These measures serve as the study’s co-primary endpoints. Furthermore, the endpoints could support a potential accelerated approval pathway. The company expects these clinical measures to provide important evidence for RP-A501. The trial remains focused on patients with Danon disease and related cardiac complications.
Modified Protocol Provides Initial Safety Findings
Rocket also provided an update on the modified RP-A501 treatment protocol. The first three patients received treatment at the recalibrated dose. All three patients completed the protocol-specified initial observation period. Importantly, they showed no clinical or laboratory evidence of thrombotic microangiopathy. They also showed no clinical or laboratory evidence of capillary leak syndrome. However, Rocket emphasized that these observations remain preliminary.
The company continues to monitor the patients through ongoing follow-up. Therefore, additional clinical information will become available as treatment monitoring progresses. The modified protocol includes a revised immunomodulation regimen. It also includes enhanced safety monitoring measures.
These changes followed safety findings from the original-dose Phase 2 study. Rocket incorporated those findings into the updated development approach for RP-A501.
Phase 1 Data Shows Sustained Biological Activity
Rocket also highlighted longer-term findings from its Phase 1 study. The principal Phase 1 analysis included six patients. At approximately 12 months, all six patients demonstrated myocardial LAMP2 protein expression. Each patient also achieved at least a 10% reduction in left ventricular mass index.
Longer-term follow-up provided additional findings. Patients had approximately three to seven years of follow-up during the analysis. At that stage, five of six patients maintained a left ventricular mass index below baseline. Four patients recorded reductions of at least 10%.
Additionally, all six patients maintained reductions in cardiac biomarkers. The patients also showed improvements in quality of life. These findings provide longer-term data for the development of RP-A501. They also add to the company’s understanding of sustained biological activity.
Original-Dose Phase 2 Findings Informed Development
Rocket also reviewed findings from the original-dose Phase 2 study. Four patients had longitudinal efficacy assessments available for analysis. Among them, three achieved at least a 10% reduction in left ventricular mass index. These results contributed to the company’s assessment of RP-A501’s clinical activity.
However, the original-dose study also identified important safety findings. These findings included thrombotic microangiopathy. The study also reported a fatal serious adverse reaction. Consequently, these findings informed several changes to the RP-A501 development program.
Rocket recalibrated the dose based on the available safety information. The company also revised the immunomodulation regimen. Furthermore, Rocket implemented enhanced safety monitoring. These measures now form part of the modified treatment protocol.
Danon Disease Patient Population
Rocket also discussed its assessment of the Danon disease patient population. Genetic and clinical analyses supported a modeled U.S. population estimate. The modeled population includes approximately 10,000 to 11,000 people. This estimate includes approximately 4,000 males.
Rocket’s initial development focus remains on males with symptomatic hypertrophic cardiomyopathy. This population represents an important focus for the company’s RP-A501 program. Danon disease is a rare genetic condition that can affect cardiac function. Therefore, developing targeted genetic medicines remains an important clinical objective.
RP-A501 remains central to Rocket’s efforts in this area. The company continues to evaluate the therapy through clinical development and long-term follow-up.
Upcoming RP-A501 Clinical Development Milestones
Rocket Pharmaceuticals has disclosed its anticipated development timeline. The company aims to finalize pivotal trial dosing by mid-2027. Once dosing is done, the company expects to receive topline results by the middle of 2028. These developments will give more clarity on the clinical development of RP-A501.
The upcoming data will also help evaluate the therapy against its predefined response criteria. Those criteria include LAMP2 protein expression and changes in left ventricular mass index. Meanwhile, Rocket will continue patient follow-up and safety monitoring. The company will also continue advancing the modified Phase 2 protocol.
To conclude, the latest update provides the next steps for RP-A501. It also provides longer term clinical data from the Phase 1 program. The company remains focused on Danon disease and symptomatic hypertrophic cardiomyopathy. The development strategy includes assessment of efficacy and continued safety monitoring.
Rocket believes that the upcoming milestones will refine the clinical path for RP-A501. The program continues to focus on an unmet need in the treatment of rare diseases.
Explore Health Tech Insiders for the latest medical innovations and reliable strategic insights driving the future of technology-driven healthcare transformation.
News Source: Businesswire.com
